Literature DB >> 12505217

Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.

Donald E Cutlip1, Manish S Chauhan, Donald S Baim, Kalon K L Ho, Jeffrey J Popma, Joseph P Carrozza, David J Cohen, Richard E Kuntz.   

Abstract

OBJECTIVES: We sought to evaluate clinical restenosis in a large population of patients who had undergone coronary stent placement.
BACKGROUND: One-year success after coronary stenting is limited mainly by restenosis of and requirement for repeat revascularization of the treated lesion. We studied 6,186 patients (6,219 lesions) pooled from several recently completed coronary stent trials. Clinical restenosis was defined using three different definitions: target lesion revascularization (TLR) beyond 30 days, target vessel revascularization (TVR) beyond 30 days, and target vessel failure (TVF), defined as TVR, any death, or myocardial infarction (MI) of the target vessel territory after hospital discharge.
RESULTS: By one year, 638 (12.2%) patients had TLR, 748 (14.3%) had TVR, and 848 (16.0%) had TVF, more than two-thirds higher than the rate of these end points at six months. The severity of angiographic restenosis (> or =50% follow-up diameter stenosis [DS]) in 419 of 1,437 (29%) patients undergoing routine angiographic follow-up correlated directly with the likelihood of TLR (73% vs. 26% for >70% DS compared with <60% DS). Smaller pretreatment minimum lumen diameter (MLD), smaller final MLD, longer stent length, diabetes mellitus, unstable angina, and hypertension were independent predictors of TLR. Prior MI and current smoking were negative predictors.
CONCLUSIONS: At one year after stenting, most clinical restenosis reflected TLR, which was predicted by the same variables previously associated with an increased risk of angiographic restenosis. The lower absolute rate of clinical restenosis relative to angiographic restenosis was due to infrequent TLR in lesions with less severe (<60% DS) angiographic renarrowing.

Entities:  

Mesh:

Year:  2002        PMID: 12505217     DOI: 10.1016/s0735-1097(02)02597-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  54 in total

1.  [Drug-coated stents. Where do we stand in 2004?].

Authors:  B Scheller
Journal:  Z Kardiol       Date:  2004-09

Review 2.  The Current Literature on Bioabsorbable Stents: a Review.

Authors:  Wally A Omar; Dharam J Kumbhani
Journal:  Curr Atheroscler Rep       Date:  2019-11-25       Impact factor: 5.113

3.  Effect of intravascular ultrasound-guided adjuvant high-pressure non-compliant balloon post-dilation after drug-eluting stent implantation.

Authors:  Yoshitaka Muraoka; Shinjo Sonoda; Yuki Tsuda; Seiya Tanaka; Masahiro Okazaki; Yutaka Otsuji
Journal:  Heart Vessels       Date:  2010-12-23       Impact factor: 2.037

4.  Characterizing the spectrum of in-stent restenosis: implications for contemporary treatment.

Authors:  Gordon E Pate; May Lee; Karin Humphries; Eric Cohen; Robert Lowe; Rebecca S Fox; Robert Teskey; Christopher E Buller
Journal:  Can J Cardiol       Date:  2006-12       Impact factor: 5.223

Review 5.  The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.

Authors:  Ping Wang; Shijie Zhou; Rui Zhou; Gan Liu; Ping Tang; Jing He; Cong Ma; Yi He; Jinliang Yang
Journal:  Clin Cardiol       Date:  2012-05-14       Impact factor: 2.882

Review 6.  Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Authors:  Moshe Vardi; Robert W Yeh; Charles A Herzog; Wolfgang C Winkelmayer; Soko Setoguchi; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 8.237

7.  Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?

Authors:  Perwaiz M Meraj; Rajiv Jauhar; Avneet Singh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-08

Review 8.  Bioresorbable Scaffolds for Coronary Artery Disease.

Authors:  Ashwin Nathan; Taisei Kobayashi; Daniel M Kolansky; Robert L Wilensky; Jay Giri
Journal:  Curr Cardiol Rep       Date:  2017-01       Impact factor: 2.931

9.  What reimbursement for coronary revascularization with drug-eluting stents?

Authors:  Rosanna Tarricone; Monia Marchetti; Mark Lamotte; Lieven Annemans; Peter de Jong
Journal:  Eur J Health Econ       Date:  2004-12

Review 10.  Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention.

Authors:  Neil J Wimmer; Robert W Yeh
Journal:  Trends Cardiovasc Med       Date:  2012-07-28       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.